Response to the JAK1/JAK3 inhibitor remained consistent regardless of baseline BMI, indicating that this treatment option is effective for individuals with moderate to severe RA, including those with a BMI ≥ 30 kg/m2 [56]. Here, JAK1 is linked to rheumatoid arthritis.